On the contrary, localised well-differentiated PanNETs, especially those <2 cm, have a more indolent behaviour with 5 years survival of 93% of patients.1 Death domain-associated protein (DAXX) and or alpha-thalassemia/mental retardation X-linked chromatin remodeler (ATRX) are mutated in almost 40% of sporadic PanNETs, often in combination with MEN1 mutations.2DAXX/ATRX mutations result in loss of nuclear expression of the protein in the tumour tissue. Here, ATRX is linked to neoplasm.